Literature DB >> 24037930

Chemoprevention of nonmelanoma skin cancer.

Razieh Soltani-Arabshahi1, Payam Tristani-Firouzi.   

Abstract

Chemoprevention is suitable for patients who are at high risk of development of numerous or invasive nonmelanoma skin cancers (NMSCs). Various substances have been studied as potential chemopreventive agents for NMSC. Oral retinoids have been proven to be effective in the suppression of new squamous cell carcinoma (SCC) development. Patients need to stay on oral retinoids as long as chemoprevention is needed with careful monitoring of the dose and side effects. Topical retinoids are not effective in prevention of NMSC. In organ transplant patients with aggressive or numerous skin cancers, decrease in the immunosuppression or switch to mammalian target of rapamycin inhibitors (sirolimus or everolimus) can be considered. Field therapy for areas of severe actinic damage with photodynamic therapy, imiquimod, 5-fluorouracil, ingenol mebutate, or diclofenac sodium may theoretically decrease the risk of SCC through treatment of precancerous changes. However, there is limited data regarding efficacy of these agents in chemoprevention of NMSC. Epidemiologic studies suggest a protective role for nonsteroidal anti-inflammatory agents in development of NMSC. Limited data support chemopreventive effect of difluoromethylornithine and T4 endonuclease V for actinic keratoses and basal cell carcinoma. Amongst dietary factors, low-fat diet, limonene from citrus fruit peel, and caffeine may protect against NMSC. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24037930     DOI: 10.1055/s-0033-1353377

Source DB:  PubMed          Journal:  Facial Plast Surg        ISSN: 0736-6825            Impact factor:   1.446


  2 in total

1.  Decision tree analysis to stratify risk of de novo non-melanoma skin cancer following liver transplantation.

Authors:  Tomohiro Tanaka; Michael D Voigt
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-23       Impact factor: 4.553

2.  Silibinin inhibits ultraviolet B radiation-induced mast cells recruitment and bone morphogenetic protein 2 expression in the skin at early stages in Ptch(+/-) mouse model of basal cell carcinoma.

Authors:  Cindy Rigby; Gagan Deep; Anil Jain; David J Orlicky; Chapla Agarwal; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2019-03-25       Impact factor: 4.784

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.